{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:27:28Z","timestamp":1793424448653,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jacc.2023.02.050","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T13:59:34Z","timestamp":1682949574000},"page":"1780-1792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"title":["Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and\u00a0Outcomes"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2872-9608","authenticated-orcid":false,"given":"Thomas C.","family":"Gilliland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mohebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Miksenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Haidermota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingdi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim Rosado","family":"Cristino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auris","family":"Browne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Plutzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-9494","authenticated-orcid":false,"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8402-7435","authenticated-orcid":false,"given":"Pradeep","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2023.02.050_bib1","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics\u20142021 update","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.02.050_bib2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jama.2021.3632","article-title":"Lipoprotein(a) and cardiovascular diseases","volume":"326","author":"Miksenas","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2023.02.050_bib3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamacardio.2020.5398","article-title":"Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease","volume":"6","author":"Trinder","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2023.02.050_bib4","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-018-05747-8","article-title":"Deep-coverage whole genome sequences and blood lipids among 16,324 individuals","volume":"9","author":"Natarajan","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2023.02.050_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ng.314","article-title":"Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease","volume":"41","author":"Tr\u00e9gou\u00ebt","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2023.02.050_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacc.2021.11.055","article-title":"Repeat measures of lipoprotein(a) molar concentration and cardiovascular risk","volume":"79","author":"Trinder","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.02.050_bib7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2023.02.050_bib8","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.050_bib9","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2023.02.050_bib10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2023.02.050_bib11","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.02.050_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.02.050_bib13","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.02.050_bib14","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.02.050_bib15","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1093\/eurheartj\/ehy862","article-title":"Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment","volume":"40","author":"Stiekema","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.02.050_bib16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.jacc.2023.02.050_bib17","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2023.02.050_bib18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2023.02.050_bib19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2023.02.050_bib20","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A\u00a0novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2023.02.050_bib21","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2023.02.050_bib22","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.jacc.2009.02.041","volume":"53","author":"Fraley","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.02.050_bib23","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.jacc.2006.03.001","article-title":"Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease","volume":"47","author":"Tsimikas","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.02.050_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.02.050_bib25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamacardio.2017.3833","article-title":"Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-Outcomes randomized clinical trial","volume":"3","author":"Schwartz","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2023.02.050_bib26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O\u2019Donoghue","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.02.050_bib27","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1194\/jlr.RA120000830","article-title":"Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a)","volume":"61","author":"Gonen","year":"2020","journal-title":"J\u00a0Lipid Res"},{"issue":"8","key":"10.1016\/j.jacc.2023.02.050_bib28","article-title":"Development and validation of an isoform independent monoclonal antibody-based ELISA for measurement of lipoprotein(a)","volume":"63","author":"Maroccia","year":"2022","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2023.02.050_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcme.2014.08.005","article-title":"Design, methods, baseline characteristics and interim results of the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study","volume":"5","author":"Gaggin","year":"2014","journal-title":"IJC Metab Endocr"},{"key":"10.1016\/j.jacc.2023.02.050_bib30","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2019.01.073","article-title":"Association of an HDL apolipoproteomic score with coronary atherosclerosis and cardiovascular death","volume":"73","author":"Natarajan","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.02.050_bib31","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/01.CIR.89.5.2015","article-title":"Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty","volume":"89","author":"Mark","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.02.050_bib32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.02.050_bib33","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1161\/CIRCULATIONAHA.108.836940","article-title":"Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race\/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study","volume":"119","author":"Tsimikas","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.02.050_bib34","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1161\/01.CIR.0000141728.23033.B5","article-title":"High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL Trial","volume":"110","author":"Tsimikas","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.02.050_bib35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/bmm.11.60","article-title":"Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events","volume":"5","author":"Taleb","year":"2011","journal-title":"Biomark Med"},{"key":"10.1016\/j.jacc.2023.02.050_bib36","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2023.02.050_bib37","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1161\/01.CIR.90.4.1688","article-title":"A\u00a0prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study","volume":"90","author":"Bostom","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.02.050_bib38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0021-9150(02)00026-6","article-title":"Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study","volume":"163","author":"Luc","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2023.02.050_bib39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/cvr\/cvu107","article-title":"Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts","volume":"103","author":"Laschkolnig","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2023.02.050_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154706","article-title":"Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors","volume":"116","author":"Ong","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2023.02.050_bib41","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jacl.2018.02.007","article-title":"Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease","volume":"12","author":"Verweij","year":"2018","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2023.02.050_bib42","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk","volume":"79","author":"Mehta","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.02.050_bib43","article-title":"Predicting cardiovascular outcomes by baseline lipoprotein(a) concentrations: a large cohort and long-term follow-up study on real-world patients receiving percutaneous coronary intervention","volume":"9","author":"Liu","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2023.02.050_bib44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.02.050_bib45","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2023.02.050_bib46","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jcin.2021.07.042","article-title":"Association of lipoprotein(a) with recurrent ischemic events following percutaneous coronary intervention","volume":"14","author":"Yoon","year":"2021","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2023.02.050_bib47","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.02.050_bib48","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2016.01.005","article-title":"Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)","volume":"10","author":"Yeang","year":"2016","journal-title":"J\u00a0Clin Lipidol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723050192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723050192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:57:14Z","timestamp":1760018234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109723050192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":48,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0735109723050192"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2023.02.050","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and\u00a0Outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2023.02.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}